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Omi/HtrA2 is a nuclear-encoded mitochondrial serine
protease that has a pro-apoptotic function in mamma-
lian cells. Upon induction of apoptosis, Omi translocates
to the cytoplasm and participates in caspase-dependent
apoptosis by binding and degrading inhibitor of apopto-
sis proteins. Omi can also initiate caspase-independent
apoptosis in a process that relies entirely on its ability to
function as an active protease. To investigate the mech-
anism of Omi-induced apoptosis, we set out to isolate
novel substrates that are cleaved by this protease. We
identified HS1-associated protein X-1 (HAX-1), a mito-
chondrial anti-apoptotic protein, as a specific Omi inter-
actor that is cleaved by Omi both in vitro and in vivo.
HAX-1 degradation follows Omi activation in cells
treated with various apoptotic stimuli. Using a specific
inhibitor of Omi, HAX-1 degradation is prevented and
cell death is reduced. Cleavage of HAX-1 was not ob-
served in a cell line derived from motor neuron degen-
eration 2 mice that carry a mutated form of Omi that
affects its proteolytic activity. Degradation of HAX-1 is
an early event in the apoptotic process and occurs while
Omi is still confined in the mitochondria. Our results
suggest that Omi has a unique pro-apoptotic function in
mitochondria that involves removal of the HAX-1 anti-
apoptotic protein. This function is distinct from its abil-
ity to activate caspase-dependent apoptosis in the cyto-
plasm by degrading inhibitor of apoptosis proteins.
Omi/HtrA2 is a mitochondrial serine protease that is re-
leased to the cytoplasm upon induction of apoptosis (1–4). In
the cytoplasm, Omi binds and cleaves IAPs1 leading to activa-
tion of caspase-dependent apoptosis (5, 6). Omi can also induce
caspase-independent apoptosis through an as yet unknown
mechanism that requires its proteolytic activity (7, 8). In addi-
tion to its pro-apoptotic function, Omi has another unique role
in maintaining mitochondrial homeostasis, but the details of
this mechanism are still unclear (9). The serine protease activ-
ity of Omi is necessary and essential for its normal function
whether it acts as a pro-apoptotic protein in the cytoplasm or as
a potential chaperone in the mitochondria (9). The proteolytic
activity of Omi has been associated with autoprocessing to form
the mature protein as well as cleavage of IAPs to activate
caspase-dependent apoptosis (5, 6, 8). To understand the mech-
anism of Omi’s function, it will be necessary to identify new
substrates for this protease. These substrates might be mito-
chondrial or cytoplasmic proteins, and their degradation and
removal by Omi could be part of the apoptotic process. In this
report, we used the yeast two-hybrid system to isolate and
characterize new Omi-interacting proteins. One of these inter-
actors isolated from this screen was the HS1-associated protein
X-1 (HAX-1) anti-apoptotic protein (10). HAX-1 interacted with
Omi both in vitro and in vivo. Furthermore, HAX-1 was de-
graded and removed by Omi when cells were treated with
various apoptotic stimuli. Using a specific inhibitor of the pro-
teolytic activity of Omi, we could block HAX-1 degradation and
protect cells from apoptosis. We also used a cell line derived
from motor neuron degeneration 2 (mnd2) mice that carry a
mutated form of Omi affecting its proteolytic activity (9). There
was little degradation of HAX-1 in these cells upon induction of
apoptosis. When functional Omi was reconstituted in themnd2
cells, degradation of HAX-1 was also restored. Our present
study identified the HAX-1 protein as a new substrate for Omi.
Cleavage of HAX-1 occurs in mitochondria before Omi translo-
cates to the cytoplasm. This suggests HAX-1 degradation pre-
cedes cleavage of IAPs that takes place in the cytoplasm.
HAX-1 degradation occurs in response to various apoptotic
stimuli and requires the presence of a proteolytically active
Omi. Our results define a new mechanism by which Omi acti-
vates apoptosis from inside the mitochondria by removing the
HAX-1 anti-apoptotic protein. Furthermore, we show a very
significant inverse correlation between the level of HAX-1 pro-
tein and the degree of cell death. This suggests that the HAX-1
protein (and its regulation by Omi protease) plays a central role
in mammalian cell death.
MATERIALS AND METHODS
Yeast Two-hybrid Screen—EGY48 (MATa trp1 ura3 his3 LEU2::pLex
Aop6-LEU2) was used as the host yeast strain for all two-hybrid
interaction experiments (11). This yeast strain has both an integrated
LEU reporter gene with upstream LexA operators as well as a
pSH18–34 (LexAop-lacZ) 2  plasmid that directs the synthesis of
-galactosidase (12).
Positive protein-protein interactions between the bait and prey were
initially detected by the ability of the yeast to grow on galactose-Ura-
Trp-His-Leu-selective yeast plates. They were further tested on Ura-
His-Trp-X-gal plates. Plasmids were rescued from positive clones and
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introduced into KC8 Escherichia coli by electroporation. DNA sequence
was determined by sequencing both DNA strands with a commercially
available kit (CEQ DTCS-Quick Start kit (Beckman Coulter)) using a
CEQ 2000 DNA analysis system (Beckman Coulter). The presence and
stability of the recombinant proteins in yeast cells was monitored by
Western blot analysis with either LexA-antibodies (for baits) or HA-
antibodies (for preys).
Degradation Assay—The ability of His-Omi134–458 to cleave HAX-1 in
vitro was investigated. For this the full-length cDNA for HAX-1 protein
was cloned in the pET-28 vector (Novagen) containing the T7 promoter
and used in an in vitro transcription-translation system (Promega) in
the presence of [35S]methionine and [35S]cysteine (Amersham Bio-
sciences). Bacterially expressed recombinant His-Omi134–458 was puri-
fied on nickel-nitrilotriacetic acid affinity resin as described (13). His-
Omi134–458 (0.5 g) was incubated with
35S-labeled HAX-1 in 20 l of
reaction volume in assay buffer (20 mM Na2HPO4 (pH 8), 10% glycerol,
200 mM NaCl). After 2 or 6 h of incubation at 37 °C the reactions were
stopped through the addition of SDS-sample buffer. Reaction products
were analyzed by SDS-PAGE followed by autoradiography.
Cell Culture—HEK293 cells were grown using Dulbecco’s modified
Eagle’s medium (Invitrogen) supplemented with 10% fetal calf serum
(Hyclone), 2 mM L-glutamine, 1.5 g/L sodium bicarbonate, 1 mM sodium
pyruvate, 50 units/ml penicillin, and 50 g/ml streptomycin (Invitro-
gen). HK-2 cells were grown in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal calf serum, 15 mM Hepes, 2 mM L-gluta-
mine, 50 units/ml penicillin, 50 g/ml streptomycin, 0.4 g/ml hydro-
cortisone, 5 g/ml insulin, and 5 g/ml apotransferrin (Sigma). mnd2-
derived cell lines stably transfected with MSCV vector or MSCV-Omi
(14) were grown in Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal calf serum, 50 units/ml penicillin, 50 g/ml streptomycin
and 0.5 g/ml of puromycin (14).
In Vivo Interaction between Omi and HAX-1 Proteins—HEK293 cells
were transfected with either the pEGFP-N1 vector (Clontech) or EGFP-
OmiS/A plasmid using LipofectAMINE 2000 reagent (Invitrogen).
EGFP-OmiS/A encodes the full-length Omi protein that carries a mu-
tation that replaces the serine in position 306 with an alanine (S 3 A)
fused to EGFP protein. This mutation has been shown previously to
inactivate the proteolytic activity of Omi (6, 8). Twenty-four h after
transfection, cell lysates were prepared using radioimmune precipita-
tion assay buffer (1 phosphate-buffered saline, 1% Nonidet P-40, 0.1%
SDS) containing protease-inhibitor mixture (Roche Applied Science).
After a low spin centrifugation, the supernatant of the cell lysates was
precleared by mixing them with protein G-agarose beads (Roche Ap-
plied Science) for 1 h followed by a GFP-polyclonal antibody (Invitro-
gen) for 2 h at 4 °C. Protein G-agarose beads were then added and
allowed to bind for an additional 4 h. Immunoprecipitates were col-
lected by brief centrifugation, washed extensively with Nonidet P-40
buffer, and resolved by SDS-PAGE. They were then electrotransferred
onto a polyvinylidene difluoride membrane and treated with a mouse
monoclonal HAX-1 antibody (BD Biosciences) followed by a secondary
horseradish peroxidase-conjugated antibody.
We also investigated the potential interaction between endogenous
Omi and HAX-1 proteins. For this, HEK293 cells were grown in
100-mm dishes and subconfluent cultures were lysed using radioim-
mune precipitation assay buffer. Approximately 400 g of total protein
cell lysate was precleared using Protein G-agarose (Roche Applied
Science) for 2 h followed by incubation with Omi rabbit polyclonal
antiserum overnight at 4 °C. A control (preimmune) antiserum was also
used. Protein G-agarose beads were collected by centrifugation, washed
four times with 1 ml of radioimmune precipitation assay buffer, and
then resuspended in 50 l of SDS sample buffer. Proteins were sub-
jected to SDS-PAGE and Western blot analysis using HAX-1 mono-
clonal antibodies.
Western Blot Analysis—After various pro-apoptotic treatments, cells
were lysed using a Triton X-100 based lysis buffer (1% Triton X-100,
10% glycerol, 150 mM NaCl, 20 mM Tris (pH 7.5), 2 mM EDTA) in the
presence of a protease inhibitor mix (Roche Applied Science). Approxi-
mately 20 g of whole cell extracts were resuspended in SDS sample
buffer and boiled for 3 min. The samples were resolved on SDS-PAGE
and electrotransferred onto polyvinylidene difluoride membranes (Pall
Corporation) using a semi-dry cell transfer blot (Bio-Rad). 2% nonfat
dry milk in TBST buffer (25 mM Tris-HCl, pH 8.0, 125 mM NaCl, 0.1%
Tween 20) was used to block nonspecific binding of the membrane. The
membrane was incubated with the indicated primary antibodies:
HAX-1 monoclonal antibody at 1:300 dilution (BD Biosciences), Omi
rabbit polyclonal antibody at 1:5000 dilution (prepared in our lab),
XIAP monoclonal antibody (BD, Transduction Laboratories) at 1:500
dilution, and -actin monoclonal antibody (Sigma) at 1:5,000 dilution
followed by a secondary peroxidase-conjugated goat anti-mouse or goat
anti-rabbit antibody (Jackson ImmunoResearch) at 1:5,000 dilution;
the immunocomplex was then visualized by ECL (Pierce).
Cell Death Assays—HK-2 cells were grown in six-well plates in the
appropriate medium until they reached 80% confluence; they were then
treated with ucf-101 (50 or 70 M) for 20 min followed by cisplatin (50
M) or H2O2 (2 mM) treatment for 14 h. HEK293 cells were treated with
cisplatin (50 M) or H2O2 (1 mM) for 14 h. mnd2-derived cell lines were
treated with cisplatin (5 M), H2O2 (100 M), or etoposide (100 g/ml)
for 14 h. Cells were detached using 1 trypsin-EDTA (Invitrogen),
washed twice with ice-cold phosphate-buffered saline, and resuspended
in 1 binding buffer (BD Biosciences) according to BD Biosciences
protocol. Cell death was estimated by staining with Annexin V (apo-
ptotic cell) and 7-aminoactinomycin D (necrotic cells) (15–17). Samples
were analyzed on a FACSCalibur flow cytometer (BD Biosciences).
Subcellular Fractionation—HEK293 cells were grown in 100-mm
dishes to 80% confluence. After treatment with cisplatin (50 M) or
H2O2 (1 mM) for 14 h, cell fractionation was performed using the
ApoAlert cell fractionation kit (Clontech) according to the instructions
supplied by the manufacturer. Cells were homogenized with a tissue
grinder in a fractionation buffer mix containing protease inhibitors and
dithiothreitol. The homogenate was then centrifuged at 700  g. The
pellet representing the crude nuclear fraction was discarded. The su-
pernatant was collected and centrifuged further at 10,000 g. Both the
resultant crude pellet mitochondrial fraction and the crude supernatant
cytosolic fraction were collected. The purity of the mitochondrial frac-
tions was monitored by assaying the activity of succinate dehydrogen-
ase and cytochrome c oxidase (18). The majority of the activity of these
two enzymes was associated with the mitochondrial fraction. The frac-
tions were resolved by SDS-PAGE and Western blot analysis using the
following antibodies: Omi (1:5,000), HAX-1 (1:300), XIAP (1:500), and
cytochrome c (1:500).
Transient Expression of HAX-1 and Mitochondrial Membrane Poten-
tial (m)—HEK293 cells were plated in 12-well plates and transfected
with either the EGFP-C1 vector or EGFP-HAX-1 plasmid using Lipo-
fectAMINE 2000 (Invitrogen). Eighteen h after transfection, cells were
treated with various concentrations of cisplatin (30, 50, and 70 M) for
14 h. The percentage of apoptotic cells was estimated by staining with
Annexin V. The change in the mitochondrial membrane potential was
monitored by staining the cells with tetramethylrhodamine methyl
ester (TMRM) (Sigma) using the method described in Ref. 19 with some
modifications. Briefly, each sample (1  106 cells) was divided in three
test tubes: (a) control GFP, (b) TMRM, and (c) phycoerythrin-conju-
gated Annexin V, and incubated either at 37 °C ((b)) or at room tem-
perature ((a) and (c)) for 15 min in 1 binding buffer (BD Biosciences).
All samples were analyzed on a FACSCalibur flow cytometer (BD
Biosciences).
Statistical Analysis—All quantitative data are expressed as mean 
S.D. Differences among groups were analyzed by one-way analysis of
variance followed by Tukey’s post-hoc test. A value of p  0.05 was
considered significant.
RESULTS
Isolation of Omi Interactors—We used the yeast two-hybrid
system to screen three different cDNA libraries constructed in
the pJG4–5 vector (11, 12). We used a HeLa cDNA library (11)
as well as cDNA libraries prepared from primary human mela-
nocytes or keratinocytes.2 We selected these cDNA libraries to
screen as many diverse proteins as possible, including any
potential tissue-specific interactors. Furthermore, cDNAs en-
coding pro-apoptotic proteins might be underrepresented or
absent in cDNA libraries prepared from cell lines. The bait
used was the mature, proteolytically active form of the Omi
protein (amino acids 134–458) cloned in the pGilda (Clontech)
bait vector. Initially, we used the PL202 (11) vector and found
that constitutive high expression of the LexA-Omi134–458 was
detrimental to yeast. Therefore, we chose to use the pGilda
vector, where expression of the bait protein is under the control
of the GAL1 inducible promoter that allows expression of the
LexA-bait fusion protein only when yeast are grown in galac-
tose medium. Expression and stability of the LexA-Omi134–458
was verified by Western blot analysis using LexA antibodies
2 A. S. Zervos, unpublished data.
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(results not shown). Several interacting proteins were identi-
fied in this screen. A detailed description of these interactors
and their properties will be presented elsewhere.3 One of the
Omi interactors isolated from both the melanocyte and kerati-
nocyte cDNA libraries was the full-length HAX-1 protein. Fig.
1 shows that HAX-1 interacts specifically and strongly with
Omi in yeast. The interaction is mediated through the PDZ
domain of Omi as well as its catalytic domain.
The specificity of HAX-1 interaction with Omi in yeast was
tested using L56/HtrA1, a mammalian homolog of Omi that
has 68% amino acid sequence similarity. No interaction be-
tween HAX-1 and L56/HtrA1 was observed in this yeast two-
hybrid assay (Fig. 1A).
Interaction of Omi with HAX-1 in Mammalian Cells—To
investigate if Omi interacts with HAX-1 in vivo, HEK293 cells
were transfected with a construct encoding a proteolytically
inactive form of Omi (Omi-S/A, serine 306 was replaced with
alanine) fused to the GFP protein. GFP antibodies were used to
precipitate GFP-Omi-S/A; the presence of any HAX-1 protein in
the precipitated complex was monitored by Western blot anal-
ysis using HAX-1 antibodies. Fig. 1B shows that HAX-1 is in a
complex with GFP-Omi-S/A in HEK293 cells. Furthermore,
interaction between endogenous Omi and HAX-1 proteins was
also investigated in HEK293 cells. Polyclonal Omi antiserum
or control pre-immune serum was used to precipitate endoge-
nous Omi and any associated proteins. The presence of HAX-1
in this immunoprecipitated complex was detected by Western
blot using HAX-1 antibodies. Fig. 1D shows endogenous Omi
and HAX-1 proteins interact in HEK293 cells.
Omi Can Degrade HAX-1 Protein in Vitro—To test the ability
of Omi to cleave the HAX-1 protein in vitro, 35S-labeled HAX-1
protein was made using a TNT-Quick coupled transcription/
translation system (Promega). Bacterially made His-
Omi134–458 is an active serine protease and has been described
previously (13). Fig. 2 is an autoradiograph of an SDS-PAGE
gel showing specific cleavage of 35S-labeled HAX-1 by His-
Omi134–458 in vitro.
HAX-1 Protein Level Decreases during Cell Death—To inves-
tigate whether the level of HAX-1 protein is regulated in mam-
malian cells during cell death, we treated HK-2 cells with
various concentrations of cisplatin or H2O2. Fig. 3 shows the
protein level of HAX-1 proportionally decreases as the concen-
tration of cisplatin is raised from 30 to 70 M. HAX-1 protein
also decreased in cells treated with increasing concentration
of H2O2.
ucf-101 Inhibitor Prevents HAX-1 Degradation—We investi-
gated whether the Omi protease is specifically responsible for
the degradation of HAX-1 observed in HK-2 cells during apo-
ptosis. To accomplish this, HK-2 cells were treated with cispla-
tin and the percentage of cell death was monitored by flow
cytometry. Cell extracts were also prepared from the same cell
populations, and the levels of HAX-1 or Omi proteins were
monitored by Western blot analysis. HK-2 cells treated with 50
M cisplatin for 14 h resulted in 94% cell death of the popula-
tion (Fig. 4). The cell death in these cells coincided with a
dramatic reduction in the level of HAX-1 protein. When the
same experiment was performed in the presence of ucf-101, a
specific inhibitor of the proteolytic activity of Omi, the percent-
age of apoptotic cells decreased to 66%. HAX-1 degradation was
also inhibited in the presence of ucf-101. At the higher concen-
tration of 70 M ucf-101, cisplatin-induced apoptosis of HK-2
cells was further reduced to 48%. At this higher concentration,
ucf-101 also had a more pronounced effect in blocking HAX-1
degradation. The level of Omi protein in HK-2 cells did not
show any significant variation under any of these conditions.
HAX-1 Is Not Degraded in mnd2 Cells That Carry an Inac-
tive Omi Protease—To further validate that Omi, and not some
other protease, is responsible for HAX-1 degradation during
apoptosis, we used cell lines derived from mnd2 mice (9, 20).
3 M. M. Soundarapandian, G. A. Kyriazis, L. Cilenti, and A. S. Zervos,
unpublished data.
FIG. 1. Interaction of HAX-1 with
Omi serine protease. A, interaction and
specificity of HAX-1 with different do-
mains of Omi protein. Yeast colonies were
transformed with plasmids encoding the
indicated baits and full-length HAX-1 as
prey (11); blue color results from a posi-
tive protein-protein interaction. L56/
HtrA1 is a mammalian homolog of Omi
(23). B, association of HAX-1 with Omi in
mammalian cells. Cells were transfected
with either EGFP or EGFP-OmiS/A.
Twenty-four h later, cell lysates were pre-
pared as described under “Materials and
Methods.” GFP antibodies were used to
immunoprecipitate proteins that were
subjected to SDS-PAGE and transferred
to a polyvinylidene difluoride membrane,
and the presence of HAX-1 was detected
using specific antibodies. Lane 1 shows an
absence of HAX-1 in cells transfected with
empty EGFP vector; lane 2 shows that
HAX-1 has co-precipitated with EGFP-
Omi-S/A. C, the same blot was also incu-
bated with anti-GFP antibodies to show
expression and stability of the GFP-fusion
proteins. D, co-immunoprecipitation of
endogenous Omi and HAX-1 proteins.
HEK293 cells were lysates, and Omi an-
tibodies were used to precipitate endoge-
nous protein. Immunoprecipitated com-
plexes were analyzed as described in B.
HAX-1 co-precipitated with Omi (lane 2)
but not when pre-immune serum was
used (lane 1).
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These mice carry a single mutation in the Omi gene that
changes the amino acid serine in position 276 to a cysteine; this
amino acid substitution abolishes the proteolytic activity of
Omi (9).mnd2mouse embryonic fibroblasts were immortalized
and then stably transfected with an empty vector (mnd2-
MSCV) or a vector expressing human Omi (mnd2-MSCV-Omi)
(14). Apoptosis was induced in these two cell lines using vari-
ous stimuli, and the percentage of cell death was estimated.
HAX-1 and Omi protein levels were also monitored by Western
blot analysis. The three different apoptotic stimuli employed
induced cell death in mnd2-MSCV-Omi cells to various de-
grees. Under these conditions, H2O2 induced more cell death
than etoposide or cisplatin. The level of HAX-1 protein was
dramatically decreased during apoptosis in these cells, and
there was an inverse correlation between the level of HAX-1
protein and the percentage of apoptotic cells (Fig. 5).
When the same experiment was performed with the mnd2-
MSCV parental cell line that carries the mutated Omi protein,
the results were very different. The percentage of apoptotic
cells after treatment was significantly lower when compared
with mnd2-MSCV-Omi cells. Furthermore, no significant
HAX-1 degradation was observed in these cells. The level of
Omi protein was much higher in the mnd2-MSCV-Omi cells
than in the parental cell line (mnd2-MSCV) presumably caused
by multiple copies of Omi gene introduced during transfection
(Fig. 5).
Omi-induced HAX-1 Degradation Occurs in the Mitochon-
dria—HAX-1 protein is reported to be present in the mitochon-
dria as well as in the cytoplasm (10, 21). We investigated where
in the cell Omi-induced degradation of HAX-1 occurs. Fig. 6
shows that the HAX-1 protein is present in the mitochondria.
During induction of apoptosis with cisplatin or H2O2, HAX-1
remained in the mitochondria, and its protein level dramati-
cally decreased. XIAP, on the other hand, is found in the
cytoplasm and there was a decrease in its protein level after
induction of apoptosis. The protein level of Omi in the cyto-
plasm increased after the pro-apoptotic treatment because of
its release from the mitochondria (1, 2). Some Omi protein
remained associated with the mitochondrial fraction even after
induction of apoptosis. Cytochrome cwas also released from the
mitochondria to the cytoplasm in a similar manner as the Omi
protein (Fig. 6). The small amount of XIAP protein detected in
the mitochondrial fractions as well as the cytochrome c and
Omi proteins seen in the control cell lysates are probably
caused by cross-contamination between the mitochondrial and
cytosolic fractions.
HAX-1 Overexpression Has an Anti-apoptotic Effect and Reg-
ulates Mitochondrial Membrane Potential—Previous studies
clearly demonstrated that HAX-1 has an anti-apoptotic func-
tion, but the mechanism of its action is not known (10, 22). We
tested the anti-apoptotic function of HAX-1 in our system and
any effect HAX-1 overexpression might have on the mitochon-
drial membrane potential. HEK293 cells were transfected with
EGFP-C1 vector or EGFP-HAX-1, and apoptosis was induced
using different concentration of cisplatin. Fourteen h after
treatment, the percentage of apoptotic cells was estimated by
Annexin V staining, and mitochondrial membrane potential
was monitored using TMRM followed by FACS analysis. Fig.
7B shows that the percentage of apoptotic cells (Annexin V
positive) increased when the concentration of cisplatin was
raised from 50 M to 70 M (42% to 67% annexin V positive).
Furthermore, cells transfected with EGFP-HAX-1 were signif-
FIG. 2. HAX-1 can be cleaved by Omi protease in vitro. In vitro
translated 35S-labeled HAX-1 protein was incubated at 37 °C without
(lane 1) or with 500 ng of recombinant His-Omi134–458 for 2 h (lane 2)
and 6 h (lane 3). The reactions were resolved on SDS-PAGE, and the gel
was transferred on a PDVF membrane and exposed on X-OMAT-AR
film.
FIG. 3. The level of HAX-1 protein is regulated by cisplatin or
H2O2 treatment. Total cell lysates were prepared fromHK-2 cells after
induction of apoptosis using different concentrations of cisplatin or
H2O2 for 14 h. Lane 1 shows lysates from control cells treated with
vehicle (N,N-dimethylformamide). Lanes 2, 3, and 4 show cell extracts
from HK-2 treated with 30, 50, and 70 M cisplatin, respectively. Lane
5 shows cell lysates without treatment; lanes 6, 7, and 8 contain lysates
obtained after 1, 2, and 4 mM of H2O2 treatment. In the lower panel,
-actin antibody was used to verify that equal amounts of protein were
present in each lane.
FIG. 4. ucf-101 protects HK-2 cells from cisplatin-induced apo-
ptosis and inhibits HAX-1 degradation. HK-2 cells were treated
with 50 or 70 M of ucf-101, and apoptosis was induced with 50 M
cisplatin for 14 h. Cell death was monitored using Annexin V (apopto-
sis) and 7-aminoactinomycin D (necrosis) staining and analyzed by flow
cytometry (15, 16). Extracts were prepared from the same cell popula-
tion and analyzed by SDS-PAGE and Western blot using HAX-1 and
Omi antibodies. This corresponds with increased apoptosis in the cell
population. When HK-2 cells were treated with ucf-101 followed by
cisplatin, the inhibitor substantially protected HAX-1 proteins and the
percentage of apoptotic cells was significantly reduced (lanes 4 and 6).
Lane 1 shows cell lysates obtained from untreated cells, lane 2 shows
lysates after 50 M of cisplatin, lane 3 shows lysates after treatment
with 50 M of ucf-101, lane 4 shows lysates after treatment with 50 M
of ucf-101 followed by 50 M of cisplatin, lane 5 shows cell lysates after
treatment with 70 M of ucf-101, and lane 6 shows lysates after treat-
ment with 70 M of ucf-101 followed by 50 M of cisplatin. Results
shown are means  S.D. of four independent experiments. *, p  0.05
versus cisplatin 50 M (lane 2); ‡, p  0.05 versus ucf-101cisplatin
(lane 4).
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icantly more resistant to cisplatin-induced apoptosis than cells
transfected with the empty vector pEGFP-C1 (Fig. 7B). Loss of
mitochondrial membrane potential (m) in cells overexpress-
ing HAX-1 and treated with cisplatin was also significantly
different from the control cells. This result was more pro-
nounced in cells treated with 50 M cisplatin. In these cells loss
of mitochondrial membrane potential occurred in 45% of cells
transfected with pEGFP-C1. In contrast, there was only 16%
loss of mitochondrial potential in cells transfected with EGFP-
HAX-1 (Fig. 7, A and C).
DISCUSSION
Omi is a serine protease with homology to bacterial HtrA
chaperones (23–26). It is made as a precursor protein that
translocates to the mitochondria where it is processed to the
mature form by proteolytic cleavage of a 133 amino acid amino-
terminal peptide (1, 2, 4). This cleavage exposes an AVPS
sequence motif at the new amino terminus; this motif is found
to be present in all known IAP-binding proteins (2, 4). Upon
induction of apoptosis, Omi translocates to the cytoplasm
where it binds to the baculovirus IAP repeat domain of IAPs via
its AVPS sequence motif (2, 4). This follows a specific cleavage
anddegradationofIAPsbyOmi.RemovalofIAPsinitiatescaspase-
dependent apoptosis. Omi is also able to induce caspase-
independent apoptosis via a poorly understood mechanism that
relies entirely on its ability to function as a protease (4).
While confined in the mitochondria, Omi might also have a
distinct function maintaining the mitochondrial homeostasis
(9, 27). This was suggested by the identification of a single
mutation in the Omi gene as the cause of the mnd2 phenotype
in mice (9, 20). This mutation inactivates the proteolytic activ-
ity of Omi without affecting its protein level or subcellular
localization. The phenotype of the mnd2 homozygous mice is
muscle wasting, neurodegenerative disease, and death by 6
weeks of age (9). This suggests that the primary function of
Omi in mammalian cells might be a chaperone-like activity in
the mitochondria (9). Other known apoptotic proteins, such as
cytochrome c and endonuclease G, are also found to have mun-
dane functions in healthy cells while playing different and
distinct roles in apoptosis (28). The proteolytic activity of Omi
is necessary and essential for its pro-apoptotic function as well
as its “chaperone-like” activity in the mitochondria (27). This
suggests that cleavage of specific substrates is involved in each
process. The only known substrates of Omi are the IAPs (5, 6,
8) but this helps only to explain how Omi activates caspase-de-
pendent apoptosis. Therefore, identification of new substrates
for Omi is necessary to fully understand its normal function in
mammalian cells. In this report, we used the yeast two-hybrid
system to isolate cDNAs encoding proteins that interact with
Omi with the assumption that some of them might also be
substrates for this protease. Several clones were isolated, and a
detailed description of this work will be presented elsewhere.3
One of the clones isolated multiple times from both the human
melanocyte and human keratinocyte cDNA library encoded for
HAX-1 (10). HAX-1 is a 35-kDa protein that has sequence
similarity to Nip3 protein and shares homology to the BH1 and
BH2 domains from the Bcl-2 family of proteins (10). HAX-1 was
originally isolated as an interactor of HS1 (10) and later shown
FIG. 5. HAX-1 degradation is absent
in mnd2 cells. Mouse embryonic fibro-
blasts from mnd2 mice were transformed
and then stably transfected with MSCV
vector or MSCV-Omi (14). Cells were
grown in six-well plates, and cell death
was induced with H2O2, etoposide, or cis-
platin. Cells were collected, and cell death
was monitored by flow cytometry using
Annexin V and 7-aminoactinomycin D, or
cell lysates were prepared and processed
for Western blot analysis using HAX-1 or
Omi antibodies. -actin antibody was
used to verify equal amounts of protein
were loaded in each lane. Results shown
are means  S.D. of four independent ex-
periments. *, p  0.05 versus vehicle
mnd2-MSCV-Omi; ‡, p  0.05 versus ve-
hicle mnd2-MSCV; §, p  0.05 versus
their correspondent treatment in
mnd2-MSCV-Omi.
FIG. 6. HAX-1 is cleaved in the mitochondria during induction
of cell death. HEK293 cells were treated with H2O2 or cisplatin; the
control lane represents untreated cells. After treatment, cells were
fractionated into cytosolic and mitochondrial fractions. The fractions
were resolved by SDS-PAGE and analyzed by Western blot using
HAX-1, Omi, XIAP, or cytochrome c antibodies.
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to also interact with PKD2 (21), EBNA-LP (29, 30), and K15-
Kaposi’s sarcoma proteins (22). Down-regulation of HAX-1 us-
ing antisense RNA has been shown to induce apoptosis in
HaCaT cells (31). We found that HAX-1 protein could specifi-
cally interact with Omi in yeast; this interaction involved both
the PDZ-domain and the catalytic domain of Omi. When HAX-1
was tested in the same system against L56/HtrA1, a mamma-
lian homolog of Omi with extensive similarity, no interaction
was observed. Co-precipitation experiments showed HAX-1
and Omi also associate in mammalian cells. Omi was also able
to cleave HAX-1 in vitro. Because HAX-1 has been reported to
be an anti-apoptotic protein (10, 22), we investigated if it is
removed during apoptosis and whether Omi could be the pro-
tease responsible for its degradation. When apoptosis was in-
duced in HK-2 cells using cisplatin or H2O2, there was a dra-
matic decrease in the level of HAX-1 protein.
To show that HAX-1 degradation is part of the apoptotic
process and any involvement Omi may have, we used the
ucf-101 inhibitor. ucf-101 is a specific inhibitor of the proteo-
lytic activity of Omi and has been described previously (13).
When HK-2 cells were treated with cisplatin in the presence of
ucf-101, the percentage of apoptotic cells decreased and the
inhibitor significantly blocked HAX-1 degradation. This effect
was more pronounced when a higher concentration of the in-
hibitor was used.
To confirm the specificity of the inhibitor in this system and
exclude the possibility that another protease rather than Omi
is involved in HAX-1 cleavage, we used cell lines derived from
mnd2mice (9). The parent cell line (mnd2-MSCV) derived from
mouse embryo fibroblasts has no detectable Omi proteolytic
activity (9). The same cell line has been transfected with wild
type human Omi cDNA (mnd2-MSCV-Omi) and expresses high
levels of active Omi protein (14). We found that inmnd2-MSCV
cells, when induced to undergo apoptosis with various stimuli,
the number of apoptotic cells was very low. Furthermore, no
detectable cleavage of HAX-1 was observed. This is in contrast
with the mnd2-MSCV-Omi cells where apoptosis was robust,
and HAX-1 levels were inversely proportional to the degree of
apoptosis. This experiment clearly shows that Omi is solely
responsible for HAX-1 cleavage, which is essential for apoptosis
under the conditions used in these experiments. HAX-1 subcel-
lular localization depends on cell type (21, 30) and has been
reported to be present in the mitochondria, cytoplasm, or
plasma membrane (10, 21, 22, 30). We performed subcellular
fractionation to investigate where HAX-1 cleavage by Omi
takes place. We found that, in HEK293 cells, HAX-1 was pre-
dominantly present in the mitochondria, and this localization
did not change in response to apoptotic stimuli. This suggests
that Omi can initiate apoptosis in the mitochondria by cleaving
HAX-1 protein. This is in accord with a recent study that shows
Omi can induce apoptosis in human neutrophils treated with
TNF- without being released from the mitochondria (7). Al-
though several studies clearly define HAX-1 as an anti-apo-
ptotic protein, the mechanism of its function is unknown.
FIG. 7. HAX-1 overexpression has an anti-apoptotic effect and regulates mitochondrial membrane potential. A, HEK293 cells were
transfected with empty EGFP vector or EGFP-HAX-1 as described under “Material and Methods.” Apoptosis was induced using 50 and 70 M of
cisplatin for 14 h. Cells were stained with either TMRM (A) or Annexin V (B), incubated at 37 °C for 15 min, and analyzed using a FACSCalibur
flow cytometer (BD Biosciences). Data are means S.D. of four independent experiments. ‡, p 0.05 versus vehicle EGFP-vector; *, p 0.05 versus
vehicle EGFP-HAX-1; §, p  0.05 versus their correspondent treatment in EGFP-vector. C, histogram showing results from a representative
experiment that measures changes in the mitochondrial membrane potential (m) in HEK293 cells over-expressing HAX-1 and treated with
cisplatin. HEK293 cells were transfected with EGFP-vector (left panel) or EGFP-HAX-1 (right panel) and treated with two different concentrations
of cisplatin, 50 M (green) or 70 M (blue). Control denotes cells treated with vehicle alone (red). The percentage of TMRM-positive cells in the
transfected population of cells is indicated.
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HAX-1 has sequence similarity to Bcl-2 family of proteins (10,
22). When we overexpressed HAX-1 protein into HEK293 cells,
the cells became significantly more resistant to cisplatin-
induced apoptosis than cells transfected with vector alone.
HAX-1-overexpressing cells were also more resistant to loss of
mitochondrial membrane potential (m) than control cells
following cisplatin treatment. This suggests that HAX-1 anti-
apoptotic function might be mediated through its ability to
block m collapse during induction of apoptosis. Therefore,
cleavage of HAX-1 by Omi in mitochondria would allow the
normal depolarization of the mitochondrial membrane leading
to the release of pro-apoptotic proteins to the cytoplasm. The
fact that both Omi and HAX-1 are localized in mitochondria
suggests the existence of yet another control mechanism that
prevents HAX-1 degradation by Omi under normal conditions,
but allows it upon induction of apoptosis. This could be
achieved through “modulator” proteins that bind to Omi after
induction of apoptosis and regulate its proteolytic activity. We
have reported previously that the proteolytic activity of Omi is
regulated and dramatically increased in the kidneys of mice
that have undergone ischemia/reperfusion (23). The presence of
modulators of the proteolytic activity of Omi was recently con-
firmed by the isolation of presenilin as a specific Omi interactor
that regulates its proteolytic activity (14). HAX-1 is not the
only anti-apoptotic protein that is cleaved and inactivated by
Omi during cell death. Ped/pea-15 has recently been identified as
a specific Omi interactor that is also degraded upon induction of
apoptosis (32). Ped/pea-15 is a cytoplasmic protein, whereas
HAX-1 is in the mitochondria. Therefore, cleavage of HAX-1 by
Omi might be an early event and defines a potential new pro-
apoptotic pathway initiated in the mitochondria. The strict in-
verse correlation we observed between the protein level of HAX-1
and the degree of cell death suggest that this protein and its
regulation by Omi play a central role in mammalian cell death.
Acknowledgment—We thank members of the Zervos lab for com-
ments and suggestions.
REFERENCES
1. Suzuki, Y., Imai, Y., Nakayama, H., Takahashi, K., Takio, K., and Takahashi,
R. (2001) Mol. Cell. 8, 613–621
2. Hegde, R., Srinivasula, S. M., Zhang, Z., Wassell, R., Mukattash, R., Cilenti,
L., DuBois, G., Lazebnik, Y., Zervos, A. S., Fernandes-Alnemri, T., and
Alnemri, E. S. (2002) J. Biol. Chem. 277, 432–438
3. Martins, L. M., Iaccarino, I., Tenev, T., Gschmeissner, S., Totty, N. F., Lem-
oine, N. R., Savopoulos, J., Gray, C. W., Creasy, C. L., Dingwall, C., and
Downward, J. (2002) J. Biol. Chem. 277, 439–444
4. Verhagen, A. M., Silke, J., Ekert, P. G., Pakusch, M., Kaufmann, H., Connolly,
L. M., Day, C. L., Tikoo, A., Burke, R., Wrobel, C., Moritz, R. L., Simpson,
R. J., and Vaux, D. L. (2002) J. Biol. Chem. 277, 445–454
5. Yang, Q. H., Church-Hajduk, R., Ren, J., Newton, M. L., and Du, C. (2003)
Genes Dev. 17, 1487–1496
6. Srinivasula, S. M., Gupta, S., Datta, P., Zhang, Z., Hegde, R., Cheong, N.,
Fernandes-Alnemri, T., and Alnemri, E. S. (2003) J. Biol. Chem. 278,
31469–31472
7. Blink, E., Maianski, N. A., Alnemri, E. S., Zervos, A. S., Roos, D., and Kuijpers,
T. W. (2004) Cell Death Differ. 11, 937–939
8. Suzuki, Y., Takahashi-Niki, K., Akagi, T., Hashikawa, T., and Takahashi, R.
(2004) Cell Death Differ. 11, 208–216
9. Jones, J. M., Datta, P., Srinivasula, S. M., Ji, W., Gupta, S., Zhang, Z., Davies,
E., Hajnoczky, G., Saunders, T. L., Van Keuren, M. L., Fernandes-Alnemri,
T., Meisler, M. H., and Alnemri, E. S. (2003) Nature 425, 721–727
10. Suzuki, Y., Demoliere, C., Kitamura, D., Takeshita, H., Deuschle, U., and
Watanabe, T. (1997) J. Immunol. 158, 2736–2744
11. Zervos, A. S., Gyuris, J., and Brent, R. (1993) Cell 72, 223–232
12. Gyuris, J., Golemis, E., Chertkov, H., and Brent, R. (1993) Cell 75, 791–803
13. Cilenti, L., Lee, Y., Hess, S., Srinivasula, S., Park, K. M., Junqueira, D., Davis,
H., Bonventre, J. V., Alnemri, E. S., and Zervos, A. S. (2003) J. Biol. Chem.
278, 11489–11494
14. Gupta, S., Singh, R., Datta, P., Zhang, Z., Orr, C., Lu, Z., DuBois, G., Zervos,
A. S., Meisler, M. H., Srinivasula, S. M., Fernandes-Alnemri, T., and Al-
nemri, E. S. (2004) J. Biol. Chem. 279, 45844–45854
15. Derby, E., Reddy, V., Kopp, W., Nelson, E., Baseler, M., Sayers, T., and
Malyguine, A. (2001) Immunol. Lett. 78, 35–39
16. Herault, O., Colombat, P., Domenech, J., Degenne, M., Bremond, J. L.,
Sensebe, L., Bernard, M. C., and Binet, C. (1999) Br. J. Haematol. 104,
530–537
17. Fantin, V. R., and Leder, P. (2004) Cancer Res. 64, 329–336
18. Gateau, O., Morelis, R., and Louisot, P. (1978) Eur. J. Biochem. 88, 613–622
19. Rasola, A., and Geuna, M. (2001) Cytometry 45, 151–157
20. Jones, J. M., Albin, R. L., Feldman, E. L., Simin, K., Schuster, T. G., Dunnick,
W. A., Collins, J. T., Chrisp, C. E., Taylor, B. A., and Meisler, M. H. (1993)
Genomics 16, 669–677
21. Gallagher, A. R., Cedzich, A., Gretz, N., Somlo, S., andWitzgall, R. (2000) Proc.
Natl. Acad. Sci. U. S. A. 97, 4017–4022
22. Sharp, T. V., Wang, H. W., Koumi, A., Hollyman, D., Endo, Y., Ye, H., Du,
M. Q., and Boshoff, C. (2002) J. Virol. 76, 802–816
23. Faccio, L., Fusco, C., Chen, A., Martinotti, S., Bonventre, J. V., and Zervos,
A. S. (2000) J. Biol. Chem. 275, 2581–2588
24. Spiess, C., Beil, A., and Ehrmann, M. (1999) Cell 97, 339–347
25. Kim, D. Y., and Kim, K. K. (2002) Acta Crystallogr. Sect. D Biol. Crystallogr.
58, 170–172
26. Krojer, T., Garrido-Franco, M., Huber, R., Ehrmann, M., and Clausen, T.
(2002) Nature 416, 455–459
27. Vaux, D. L., and Silke, J. (2003) Cell 115, 251–253
28. Kaufmann, S. H., and Hengartner, M. O. (2001) Trends Cell Biol. 11, 526–534
29. Matsuda, G., Nakajima, K., Kawaguchi, Y., Yamanashi, Y., and Hirai, K.
(2003) Microbiol. Immunol. 47, 91–99
30. Dufva, M., Olsson, M., and Rymo, L. (2001) J. Gen. Virol. 82, 1581–1587
31. Mirmohammadsadegh, A., Tartler, U., Michel, G., Baer, A., Walz, M., Wolf, R.,
Ruzicka, T., and Hengge, U. R. (2003) J. Investig. Dermatol. 120, 1045–1051
32. Trencia, A., Fiory, F., Maitan, M. A., Vito, P., Barbagallo, A. P., Perfetti, A.,
Miele, C., Ungaro, P., Oriente, F., Cilenti, L., Zervos, A. S., Formisano, P.,
and Beguinot, F. (August 24, 2004) J. Biol. Chem. 10.1074/jbc.M406317200
HAX-1 Is a Novel Substrate of Omi/HtrA2 Protease 50301
 at U
CF H
ealth Sciences Library on Septem
ber 24, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Zervos
Supriya Singh, Sanjeev Gupta, Joseph V. Bonventre, Emad S. Alnemri and Antonis S. 
Lucia Cilenti, Mangala M. Soundarapandian, George A. Kyriazis, Valerie Stratico,
Death
Regulation of HAX-1 Anti-apoptotic Protein by Omi/HtrA2 Protease during Cell
doi: 10.1074/jbc.M406006200 originally published online September 15, 2004
2004, 279:50295-50301.J. Biol. Chem. 
  
 10.1074/jbc.M406006200Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/279/48/50295.full.html#ref-list-1
This article cites 31 references, 12 of which can be accessed free at
 at U
CF H
ealth Sciences Library on Septem
ber 24, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
